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CASE PRESENTATION
A 49-year-old African American woman known to
have AIDS, a medical history of pulmonary Mycobac-
terium avium complex (MAC), and early cognitive dys-
function believed related to HIV dementia was brought
to the University of California, San Diego Medical Cen-
ter from her skilled nursing facility with a history of cough
and shortness of breath of 2 days’ duration. Because she
had been non-compliant in taking her medications, she
was admitted to the hospital for presumptive Pneumo-
cystis carinii infection or community-acquired pneumo-
nia superimposed on an exacerbation of asthma.
The patient had last been hospitalized one year pre-
viously for altered mental status. Following an exten-
sive workup, her cognitive changes were thought to
be secondary to heroin abuse and untreated HIV. She
was provided with a legal conservator and was given
antiretroviral agents. Approximately 3 weeks after start-
ing antiretroviral medication, she developed an immune
reconstitution syndrome due to occult Mycobacterium
avium infection (MAI) with mediastinal lymphadenopa-
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thy and fever. The patient underwent a thoracoscopic
lymph node biopsy and was treated with azithromycin
and ethambutol with a good response. She was trans-
ferred to a skilled nursing facility and did well for quite
some time, recovering cognitive function to the level of a
4- to 5-year-old. Two months prior to that hospitalization,
she was released from her conservatorship and was dis-
charged from the nursing home to live with her mother.
She attempted to take all her medications but admitted
to being non-adherent, because she often forgot. She had
not been taking her antiretrovirals for about one month
and had also missed her trimethoprim/sulfamethoxazole
doses. She had sustained a fall 8 weeks prior to hospi-
talization and fractured her left hip. Colposcopies for
abnormal Pap smears were complicated by bleeding and
required transfusions. A workup for this problem re-
vealed that she had an isolated Factor VII deficiency. She
also had poor nutrition due to poor dentition and had
been unable to have her teeth extracted due to her coag-
ulopathy. Her last CD4 count, when she was taking an-
tiretrovirals 3 months prior to this admission, was 175 ×
103 lL and her viral load had been undetectable. Her
AIDS-defining illness included MAI and cervical cancer.
Her medical history also was significant for a dis-
tant history of Potts disease of the spine that had
been treated, and active tuberculosis had been ruled
out. The history also included diabetes mellitus, a dis-
tant history of deep-vein thrombosis, gastrointestinal
bleeding, asthma, hepatitis C, oral thrush, and intra-
venous drug use one year previously. She was hepatitis
A immune, hepatitis B core antibody positive, surface
antibody negative, toxoplasmosis positive, cryptococcal
antigen negative, and cytomegalovirus IgG positive; her
last pneumococcal vaccine was in 1998. She had no
known drug allergies and on admission was supposed
to have been taking azithromycin, 600 mg/day; etham-
butol, 900 mg/day; fluconazole, 100 mg/day; furosemide,
20 mg/day; sulfamethoxazole, double strength once daily;
lamivudine, 300 mg/day; lopinavir; ritonavir, 3 capsules
twice daily; tenofovir, 300 mg/day; calcium, 600 mg/day;
fluticasone, 220 lg twice daily; aspirin, once daily; tra-
zodone, 150 mg at night; and paroxetine, 20 mg/day. She
smoked one pack of cigarettes daily, denied alcohol or
drug use for over a year, and was not sexually active.
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On admission she was alert. The respiratory rate was
42 breaths/min; heart rate, 115 beats/min; blood pressure,
120/60 mm Hg; and she was afebrile. Her oxygen satura-
tion was 98% on a 96% high-flow face mask. She weighed
160 lbs and was 5 feet, 4 inches tall. The physical exami-
nation was remarkable for anicteric sclera, equal reacting
pupils, no lymphadenopathy, normal heart sounds with no
murmur or rub, clear lung fields with a few basilar rales,
a soft, non-tender abdomen with normal bowel sounds,
and edema of both legs. Laboratory studies on admission
revealed normal electrolytes, with a BUN and serum cre-
atinine of 4 mg/dL and 0.9 mg/dL, respectively; serum bi-
carbonate of 22 mEq/L; albumin, 1.6 g/dL; AST, 71; ALT,
17; LDH, 471; alkaline phosphatase, 153 U/L; and biliru-
bin, 1.6 mg/dL. The white blood cell count was 23.8 × 103
mL; hemoglobin, 9.7 mg/dL; hematocrit, 28.9%; platelet
count, 148 × 103 lL; and INR 1.6. Urinalysis showed trace
protein and moderate bilirubin and no cells or casts. The
pH was 7.36; PCO2, 45 mm Hg; and PO2, 117 mm Hg.
Blood and sputum cultures were negative and a chest ra-
diograph showed bilateral air-space opacities. A CT scan
of her neck and thorax showed ground-glass opacities and
nodules throughout the parenchyma that were smaller
than those seen on a CT 3 months prior.
Over the course of 24 hours, the patient’s respira-
tory status deteriorated and she was intubated. An-
tiretroviral therapy was not started, given the risk of an
immune reconstitution syndrome. She was given broad-
spectrum antibiotics. She continued to have increasing
oxygen requirements with increasing opacities in her lung
parenchyma; the clinical diagnosis was acute respiratory
distress syndrome (ARDS). She continued to be fairly
stable hemodynamically and was excreting 1 to 2 liters of
urine per day until day 14 of the hospitalization, when she
had a sudden decrease in her blood pressure to 80/40 mm
Hg, was placed on vasopressor support, and became olig-
uric. A nephrology consultation was requested with the
possible thought of initiating continuous renal replace-
ment therapy.
On examination, she was paralyzed and intubated
on pressure support ventilation with 100% FiO2, tidal
volume of 400 mL/min, PEEP 12 cm water at a venti-
lation rate of 16/min, and maintaining an oxygen satu-
ration of 92%. Her blood pressure was 109/60 mm Hg;
phenylephrine was increased to 160 lg/kg/min and vaso-
pressin to 0.04 lg/kg/min. She was edematous and had
distant heart sounds with no murmur. Examination of
the lungs revealed decreased air entry to both lung fields
up to the mid-lung, with diffuse bilateral rhonchi. Her
abdomen was soft and non-tender, and bowel sounds
were present. The extremities showed 2+ edema. Lab-
oratory tests revealed: sodium, 140 mEq/L; potassium,
4 mEq/L; chloride, 102 mEq/L; bicarbonate, 26 mEq/L;
uncorrected anion gap 12 (corrected 18); BUN, 16 mg/dL;
creatinine, 1.3 mg/dL (baseline at admission, 0.9 mg/dL);
glucose, 358; albumin, 1.6 g/dL; calcium, 9 mg/dL; inor-
ganic phosphate, 4.4 mg/mL; magnesium, 2.6 mEq/L; tro-
ponin, 1.8; and aspartate aminotransferase (AST), 425.
The white blood cell count was 19.2, and differential
counts showed 70 segmented polymorphonuclear cells
and 4 bands; hemoglobin was 8.4 mg/dL; hematocrit,
25.2%; and platelets, 146,000 mm2. Blood gases revealed
a pH of 6.97; PCO2, 110 mm Hg; PO2, 73 mm Hg; and
oxygen saturation of 93%. Urine output was <5 mL/hour,
although it had been 1200 mL over the previous 24 hours.
Overall net fluid status was 12 liters positive since ad-
mission, and she had received 2 liters of fluid over the
previous 6 hours.
DISCUSSION
DR. RAVINDRA L. MEHTA (Professor of Clini-
cal Medicine, Division of Nephrology, Department of
Medicine, UCSD Medical Center; and University of
California, San Diego; San Diego, California): This pa-
tient illustrates a relatively common scenario for clini-
cians managing critically ill patients. The development
of hypotension and oliguria in the setting of multiorgan
failure often prompts a request for continuous renal re-
placement therapy (CRRT) to be initiated. Before using
CRRT, one should assess several factors: the therapeutic
potential, goals for management, practicality of deliver-
ing CRRT, and the likelihood of improving survival.
Therapeutic potential for CRRT techniques
Continuous renal replacement therapy can be utilized
to remove or add solutes and fluid, regulate volume and
plasma composition, and prevent toxicity. The ability to
achieve each of these goals depends on the operational
characteristics of the specific type of CRRT utilized and
how it is applied.
Continuous therapies encompass a variety of modali-
ties that vary in their operational characteristics. Solute
removal is achieved either by convection, diffusion, ad-
sorption, or a combination of these methods. Convective
techniques such as continuous venovenous hemofiltra-
tion (CVVH) generally utilize ultrafiltration rates of 1 to
3 liters per hour. However, high-volume hemofiltration
with 6 liters of ultrafiltrate produced every hour has been
used to remove middle- and large-molecular-weight cy-
tokines in sepsis [1, 2]. Fluid balance is achieved by replac-
ing the ultrafiltrate removed with a replacement solution.
The composition of the replacement fluid can be varied,
and the solution can be infused before or after the filter. In
contrast to intermittent hemodialysis (HD) and slow low-
efficiency dialysis (SLED), diffusion-based continuous
techniques have dialysate flow rates that are significantly
slower than the blood flow rates (17–34 mL/min versus
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Fig. 1. CRRT circuit using regional citrate anticoagulation with the Gambro PRISMA machine and M-100 filter.
100–200 mL/min); this difference results in complete sat-
uration of the dialysate [3]. Small molecules are pref-
erentially removed by these methods. Hemodiafiltration
(HDF) uses both diffusion and convection in the same
technique [4]. Hybrid techniques are now emerging that
utilize the basic principles of CRRT and combine convec-
tive and diffusive clearances with selective adsorption of
solutes to the CRRT membrane. These therapies vary
in what is processed (blood, plasma, or ultrafiltrate), the
components (membrane sorbents or cell-based systems),
and the sequence of convective, diffusive, and adsorptive
clearances (in parallel, in series, or concurrently). These
techniques (reviewed in [5]) are still largely experimental
but will likely be increasingly utilized in the future.
Solute removal in CRRT is governed by the charac-
teristics of the membrane, the force applied (convection,
diffusion, adsorption, or a combination), and the site of
infusing the replacement fluid (pre versus post filter). The
sieving coefficient [SC = solute concentration in ultrafil-
trate (UF)/(solute concentration in plasma at filter inlet
plus plasma concentration at filter outlet/2)] describes the
properties of the membrane that dictates solute removal
in convective circuits. Protein-bound solutes or those that
exceed the molecular weight cutoff (generally 20,000 dal-
tons for polysulfone and polyacrylonitrile membranes)
have sieving coefficients less than 1. In diffusion-based
circuits, because of complete saturation of the dialysate,
the computation of UF/plasma solute concentrations sim-
ilarly represents the permeability of the membrane. In
all forms of CRRT, the “effluent” from the filter repre-
sents the end product of the filtration process and com-
prises the ultrafiltrate in CVVH, the spent dialysate in
CVVHD, and the combination of the ultrafiltrate and
spent dialysate in CVVHDF. Consequently, filter clear-
ance (UF × V/P) for most CRRT circuits is equal to Qef
(the effluent flow rate = V) × SC (UF/P) for most small
and middle molecules and is directly proportional to the
amount of effluent volume. Blood-side clearances often
do not match the filter clearances, as membrane adsorp-
tion modifies the amount of solute in the ultrafiltrate.
Consequently, for some solutes (such as TNF-a) that are
adsorbed by membranes, SC can be low but overall blood
clearance can be greater than filter clearance.
Continuous renal replacement therapy techniques vary
in their ability to remove small and middle molecules.
For small-sized solutes (for example, urea nitrogen,
creatinine, phosphates), filter clearances were directly
proportional to the effluent volume and did not vary sig-
nificantly with convective or diffusive removal across a
spectrum of effluent volumes (0.5–4.5 L/hr) [6]. In con-
trast, b-2 microglobulin removal was influenced by the
membrane type and the amount of convective clearance
[6]. The effect of these clearances on drug dosing also
should be considered. Drug removal largely depends on
the sieving coefficient of the drug, the degree of protein
binding, and the ultrafiltration rate. The pharmacokinet-
ics of different drugs in CRRT and guidelines for dosing
have been described [7–9].
Clearance of molecules in CRRT circuits also depends
on the site of replacement solution administration either
pre or post filter (Fig. 1). Removal of ultrafiltrate across
the filter concentrates the cellular elements and proteins
in the blood emerging from the filter and is directly pro-
portional to the ratio of ultrafiltrate to plasma flow rate
(filtration fraction = FF). Previous studies have demon-
strated that FF >20% contributes to reduced filter per-
formance and filter clotting. Consequently, if UF rates
are increased, the blood flow rate should be increased
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Table 1. Comparison of techniques
IHD SLED/EDD SCUF CVVHa CVVHDa CVVHDFa PD
Access VV VV AV or VV VV VV VV Peritoneal
catheter
Membrane permeability Variable Variable High High High High Peritoneal
Anticoagulation Short Long Prolonged Prolonged Prolonged Prolonged None
Blood flow rate mL/min 250–400 100–200 <100 200–300 100–200 100–200 –
Dialysate flow mL/min 500–800 100 0 0 16.7–33.4 16.7–33.4 0.4
Filtrate L/day 0-4L 0-4L 0-4L 24–96 0 24–48 2.4
Replacement fluid L/day 0 0 0 21.6–90 4.8 23–44 0
Effluent saturation% 15–40 60–70 100 100 85–100 85–100
Dialysate base Acetate + Acetate + – – Lactate, bicarbonate, Lactate, bicarbonate, Lactate,
bicarbonate bicarbonate none (citrate) none (citrate) bicarbonate
Replacement fluid base – – – Lactate, – Lactate, –
bicarbonate bicarbonate
Solute clearance mechanism Diffusion Diffusion Convection Convection Diffusion Both Both
Urea clearance mL/min 180–240 75–90 1.7 16.7–67 21.7 30–60 8.5
Duration hours 3–4 8–12 Variable >24 >24 >24 >24
Abbreviations are: SCUF, slow continuous ultra-filtration; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; CVVHDF,
continuous venovenous hemodiafiltration. Modified from Mehta RL [87].
a In the absence of pumps, arteriovenous circuits can be utilized to provide continuous therapy (CAVH, continuous arteriovenous hemofiltration; CAVHD,
continuous arteriovenous hemodialysis; CAVHDF, continuous arteriovenous hemodiafiltration). A key limitation of AV methods is that the blood flow rate cannot be
controlled and, consequently, the ultrafiltration rates and solute clearances are variable.
to maintain FF less than 20%. Clark et al have modeled
the maximum ultrafiltration rate that can be sustained
for any given blood flow rate to maintain FF <20% [10].
In convective removal, the only way to increase solute
clearances is to increase the amount of ultrafiltrate gen-
erated and consequently increase the volume of replace-
ment fluid given. When replacement fluid is infused post
filter, solute clearance is equal to SC × Qef. Pre-dilution
fluid replacement reduces the FF and reduces the solute
concentration in the blood entering the filter. The effec-
tive small-solute clearance for pre-dilutional hemofiltra-
tion is equal to Qef × (Qb/[Qb + Qr]), where Qb and Qr
represent blood and replacement fluid rates. Clearance in
pre-dilution hemofiltration is less than in post-dilutional
hemofiltration for the same Qef. However, because of
the dilution of blood entering the filter, much higher
filtration fractions (larger Qef and Qr) are feasible in
pre-dilutional hemofiltration [11]. Troyanov et al have
calculated the effect of pre-filter dilution on filter clear-
ances for various solutes for a CVVH circuit of 4.5 L/hr
effluent volume where all the fluid is given predilution
[6]. Observed decreases in clearances ranged from 31%
to 40% for urea, creatinine, and phosphates, and 40% to
45% for b 2-microglobulin. Hemofiltration circuits thus
are more vulnerable to alterations in FF and pre-dilution
fluid for dose delivery.
Dialysate “flow across” the membrane markedly im-
proves clearances by diffusion and retains the simplicity
of the procedure. Combining convection and diffusion al-
lows flexibility in enhancing middle- and small-molecule
clearances by increasing the volume of ultrafiltrate and
dialysate, respectively [3, 4, 12, 13]. Additionally, since
overall solute clearance is derived from both convec-
tive and diffusive components, it is easier to maintain
FF within the optimal range at a relatively low blood
flow rate. Adsorptive clearances depend upon the se-
lective or non-selective binding of molecules to the fil-
ter membrane. In general, the adsorptive capacity varies
and, depending on the membrane’s surface area and
binding characteristics, saturation of adsorptive sites will
occur before the filtration capacity is reduced. Adsorp-
tive clearances for middle molecules are time-dependent,
with maximal values occurring in the initial few hours of
therapy [6]. In septic patients treated with CRRT, filter
adsorption was saturated within 6 to 8 hours [14]. Most
CRRT circuits currently do not manipulate the adsorp-
tive capacity of the membranes; however, this is likely
to be utilized more commonly as hybrid technologies
evolve.
While utilizing the same forces for solute and fluid
removal, CRRT techniques are operationally different
from intermittent techniques. The major difference is that
time is no longer a limiting factor for blood purification
(Table 1). As a consequence, it is possible to use slower
blood and dialysate flow rates and achieve weekly clear-
ances that are equivalent—and often superior—to inter-
mittent techniques. The effect of time on different solute
clearances is best demonstrated by comparing equivalent
kidney clearances [15] (Table 2).
In intermittent techniques, hemodynamic instabil-
ity, shortened dialysis times, and logistic factors often
adversely affect the dose delivered [16]. In CRRT, main-
taining filter performance is also key to achieving a con-
tinuous solute removal rate; however, because the time
for clearance is increased, there is more of a “cush-
ion” to compensate for increased demand and decreased
efficiency.
Continuous renal replacement therapy techniques of-
fer a significant advantage over intermittent dialysis
for fluid control and management of acid-base and
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Table 2. Comparison of small, middle and large solute clearances
across various modalities
Parameter Modality
Solute CVVH Daily HD SLED
Urea Nitrogen TAC 40.3 64.6 43.4
EKR 33.8 21.1 31.3
Inulin TAC 25.4 55.5 99.4
EKR 11.8 5.4 3.0
Beta 2 Microglobulin TAC 9.4 24.2 40.3
EKR 18.2 7.0 4.2
Abbreviations are: TAC, time averaged concentration (mg/dL); EKR,
equivalent renal clearance (mL/min) = G/TAC; CVVH, 31/hr, pre-dilution;
Daily HD, BFR 350 mL/min, dialysate flow rate 600 mL/min, 4 hrs session 6
times per week; SLED, BFR 200 mL/min, dialysate flow rate 100 mL/min, 12 hrs
session 7 days per week.
G = generation based on a 70 kg patient with initial volume excess of 10 liter,
initial blood urea nitrogen (BUN) 90 mg/dl, initial inulin 100 mg/L, initial b2M
20 mg/L, nPCRv 1.8 g/kg/d, inulin G 0.3 mg/min, b2M G 0.17 mg/min.
Modified from Liao Z [15].
electrolyte imbalances [17–19]. Acid-base balance de-
pends on the underlying acid-base disturbance, the oper-
ational characteristics of the procedure, the amount and
type of base used, and the site of delivery of the base.
A consequence of all CRRT methods is the ongoing loss
of bicarbonate and electrolytes across the filter generally
equivalent to the plasma concentration of these solutes
times the total effluent (ultrafiltration and dialysate) flow
rates [20]. Bicarbonate losses can be replaced by addi-
tion of sodium bicarbonate or other base (for example,
lactate, acetate, citrate) to replacement solution admin-
istered intravenously, addition of base to the dialysate,
or by a combination of these techniques [21]. One of the
major advantages of CRRT is that the composition of re-
placement fluid and dialysate can be modified to achieve
any specific change in plasma composition [22].
Several centers use standard hemofiltration solutions
that have predetermined concentrations of base, usually
lactate, and ions; however, in many instances customized
solutions need to be made [23–28]. When base solutions
other than bicarbonate are used, replacement of buffer
stores depends on the metabolic rate for conversion to bi-
carbonate. In the absence of lactic acidosis, endogenous
lactate clearance does not appear to be impaired. How-
ever, the filter clearance of lactate accounts for only 2.4%
of overall lactate clearance [28].
The beneficial role of bicarbonate as buffer instead
of lactate has been investigated [29]. Hilton et al [25]
have shown that bicarbonate-based solutions are associ-
ated with improved hemodynamic stability, although no
difference was found by Thomas et al [26], who com-
pared lactate- and bicarbonate-based solutions. Addi-
tional clinical studies have confirmed that lactate-based
substitution fluids foster hemodynamic stability [30]. Use
of lactate as base has been associated with an increase
in urea generation and possibly is related to increased
catabolism [31]. Additionally, the ability to convert lac-
tate to bicarbonate might be impaired in the setting
of hypotension and multi-organ failure and could con-
tribute to the deleterious effects of lactate accumulation
[25].
One practical issue with the use of bicarbonate-based
solutions is that it is difficult to store premixed bicarbon-
ate solutions. LeBlanc et al [32] advocate preparing a
non-sterile bicarbonate solution using a standard
hemodialysis machine. This method has been used suc-
cessfully at the Cleveland Clinic and other centers [33].
However, the risk for infection is unknown, particularly
if the solutions are stored for several hours or days prior
to use [34]. This is particularly important if there is any
backfiltration as can occur in a non-integrated CRRT
system using an infusion pump to control the ultrafil-
trate. Another factor to consider is that premixed solu-
tions containing calcium and bicarbonate show evidence
of microprecipitation of calcium carbonate crystals, and
this should be avoided [35]. Citrate-based anticoagu-
lation offers an alternate method for acid-base man-
agement, as the citrate is converted in the liver and
muscle to bicarbonate. The combination of citrate antico-
agulation and bicarbonate-containing solutions has been
used effectively to manage complex acid-base disorders
[23, 36–39]. We utilize standard citrate orders to allow
our pharmacy to make the appropriate dialysis solution.
Our standard formulation uses 1 liter of 0.45% saline, to
which is added 40 mL of 23% saline (yielding a sodium
concentration of 117 mEq/L and a chloride concentra-
tion of 121.5 mEq/L), 1.5 mEq/L of magnesium, and 0–5
mEqL of potassium. We use a dialysate dextrose con-
centration of 0.1% [23]. In some circumstances, we add
bicarbonate to the dialysate, substituting the 23% NaCl
with NaHCO3 so that the final concentration of sodium is
117 mEq/L.
Continuous renal replacement techniques have three
inherent characteristics that make them highly effective
and versatile methods for fluid control [18]: (1) the use of
highly permeable membranes, (2) the infusion of various
replacement solutions, and (3) the continuous nature of
the techniques. These factors permit fluid removal that
is limited only by the primary driving force (mean arte-
rial pressure for non-pumped systems, pump speed for
pumped systems), the efficacy of the filter over time, and
the availability of sterile replacement solutions. Adjust-
ments in the ultrafiltration and replacement fluid rates
allow CRRT techniques to serve as fluid regulatory sys-
tems that can maintain fluid balance without compromis-
ing the system’s ability to maintain metabolic balance. A
major distinction for these methods is the ability to dis-
sociate solute removal (for example, sodium) from fluid
balance. As an example, by varying the composition of
the replacement fluid or dialysate, solute balance can be
altered while overall fluid balance can be kept even, neg-
ative, or positive [18].
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Table 3. Techniques for fluid balance in CRRT
Variable Common Alternate
Intake Variable Variable
Non-CRRT output Variable Variable
Ultrafiltration rate Variable to achieve fluid balance Fixed to achieve target effluent volume
Substitution fluid rate Fixed = or < UFR Varies to achieve negative, zero, or positive fluid balance
Fluid balance Achieved by varying UF rate Fluid balance is achieved by adjusting amount of
substitution fluid
Key difference Output is varied to accommodate changes in intake and
fluid balance goals
Output is fixed to achieve desired solute clearance and
allow flexibility in accommodating varying intake
Advantages
Patient factors Similar to strategy for fluid removal in intermittent dialysis Keeps solute clearance constant. Allows for variation in
intake. Individualizes prescription
CRRT factors Fluid balance calculations can be deferred to longer
intervals (e.g., every 8–12 hours)
Therapy parameters dissociate clearance requirements
from fluid balance. Reduces interactions with CRRT
pump to adjust UF rates. Simplifies regimen for
caregiver. First step to utilizing CRRT for fluid
regulation
Disadvantages
Patient factors Assumes patient in static state. Mimics ESRD prescription.
Intake may fluctuate. Fluid boluses not accounted for.
Over- or undershoot common. Solute clearances
fluctuate, particularly if dependent on convection
Requires hourly calculations for amount of replacement
fluid to be given. Potential for fluid imbalances if a
balance sheet is not used
CRRT factors Requires frequent interactions with CRRT pump to adjust
UF rates. Underutilizes CRRT for fluid removal only
May require use of an external pump to achieve fluid
regulation
Fluid removal in CRRT is achieved by formation of an
ultrafiltrate. The ultrafiltration rate used depends on two
factors: the type of technique and the fluid balance re-
quirements of the patient. Most modern CRRT pumped
systems have a wide range of ultrafiltration rates that
depend on the modality used. In convective techniques
(CVVH), the ultrafiltration rate can vary from 0.5 to
12.0 L/hr, although most centers use a range of 1.0 to
3.0 L/hr. When dialysate is used (CVVHDF), almost all
the current machines limit ultrafiltration rate to a max-
imum of 2 L/hr. These operative ranges are more than
sufficient to achieve adequate fluid removal in almost all
patients. Overall fluid removal is, however, limited by the
patient’s hemodynamic status. The ability to remove large
volumes of fluid can be manipulated in several ways for
fluid balance [18]. It is important to distinguish between
fluid balance across the CRRT machine and the patient’s
overall fluid balance. The CRRT fluid balance, deter-
mined by the software in the CRRT machine, represents
the difference in volume of ultrafiltrate and replacement
and other fluids administered through the CRRT pumps
and hung on the CRRT balancing system. All CRRT sys-
tems currently available only allow the CRRT fluid bal-
ance to be negative or zero but not positive. This feature
is a legacy from intermittent hemodialysis machines that
are utilized primarily for fluid removal. Patient overall
fluid balance obviously is computed as the net difference
in volume computed from all intakes and outputs (in-
cluding the CRRT system fluids) over a given period of
time.
Patient fluid balance in CRRT can be achieved in two
ways, either by what I call the common strategy or the
alternate strategy (Table 3). Most commonly, ultrafiltra-
tion rates are varied at set intervals to match the needs for
fluid balance. A wide range of negative fluid balances can
be achieved by this technique by increasing the ultrafiltra-
tion rate in excess of intakes. However, achieving a zero
or positive fluid balance requires a reduction in the ul-
trafiltration rate coupled with an increase in the replace-
ment fluid. Fluctuations in the ultrafiltration rate alter the
effluent volume, and thus solute clearances are variable.
This becomes particularly important when clearances are
limited to 1 to 2 L of effluent volume. An alternative
approach is to set a fixed ultrafiltration rate to achieve
an effluent volume that meets the desired clearance. In
this strategy, ultrafiltration rates are always greater than
all intakes, and a negative, zero, or positive overall fluid
balance is achieved by varying the amount of replace-
ment fluid. This method has several advantages: it allows
a fixed clearance to be delivered, accommodates fluctu-
ations in fluid intake, individualizes the prescription for
each patient, and permits CRRT to serve as a fluid reg-
ulatory device. It also simplifies the delivery of therapy
for the caregiver because it dissociates fluid balance from
clearance parameters and minimizes adjustments to the
CRRT pumps. The effluent volume is fixed, so it is easier
to manage the practical aspects of the therapy, for exam-
ple, changes in the waste bags.
The fixed ultrafiltration rate strategy for fluid balance
can be adapted to support the varying fluid balance
need of critically ill patients. This method targets the de-
sired net balance every hour to achieve a specific hemo-
dynamic parameter, for example, central venous pres-
sure, pulmonary artery wedge pressure (PAWP), or mean
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Table 4. CRRT prescription using the Gambro PRISMA machine and M-100 filter
Setting Rationale
Machine Gambro PRISMA Available machine
Modality CVVHDF Allows combination of diffusive and convective clearance.
Consequently, UF rates can be limited and do not require high
blood flow rates for filtration fraction (FF).
Membrane M-100 0.9 m2 AN69 polyacrylonitrile membrane adequate for clearances
required.
Blood flow rate 100 mL/min Not constrained by access, adequate flow for maintaining
filtration fraction <25%.
Anticoagulation 4% tri-sodium citrate At access exit through three-way stopcock to chelate ionized
calcium and prevent clotting. Rate 160-200 mL/hr adjusted to
maintain post-filter ionized calcium 0.25–0.4 mmol/L. Provides
base from conversion of citrate to bicarbonate.
0.1 mEq/mL calcium chloride Replaces calcium removed across filter, administered through
separate central line at initial flow rate of 40–60 mL/hr and
adjusted to maintain peripheral ionized calcium of 1.12–1.32
mmol/L.
Effluent volume 2.2 L/hr Allows small solute clearance of approximately 37 mL/min,
adequate clearance to compensate for catabolic state and for
reduction due to partial pre-dilution.
Dialysate flow rate 1 L/hr Slower than blood flow rate with complete saturation of dialysate
for small solutes. Diffusive clearance = 16.7 mL/min.
Pre-dilution fluid 0.5 L/hr Administered pre-filter, pre-pump dilutes blood entering the filter
with filtration fraction of 25%.
Post-filter replacement fluid 0.7 L/hr Administered post filter in venous circuit. Volume greater than all
anticipated intake to allow fixed effluent volume and clearance.
Volume adjusted hourly to achieve desired fluid balance.
Dialysate fluid composition 0.45% saline + 40 mEq of Na as NaHCO3 or
NaCl + Mg 2.0 mEq/L + 2–5 mEq/L KCl +
0.1% dextrose
Low sodium (117 mEq/L) allows removal of sodium load in
tri-sodium citrate (Na = 420 mmol/L, citrate 140 mmol/L),
varying amounts of bicarbonate added to provide extra base for
correction of acidosis and compensate for bicarbonate loss
across filter, no calcium allows removal of citrate-calcium
chelate.
Pre-dilution fluid composition 0.9% saline Isotonic for diluting blood.
Post-filter fluid composition 0.9% saline, 0.45% saline + 75 mEq/L of
sodium bicarbonate, sterile water + 150
mEq/L of sodium bicarbonate
Normal saline adequate to maintain normal sodium levels.
Additional bicarbonate added to solutions depending on
acid-base status and bicarbonate requirement.
Monitoring Serum electrolytes and blood gases Initially every 12 hours then every 24 hours, adjust solutions
composition.
Post-filter ionized calcium Every 12 hours: adjust citrate flow rates.
Peripheral ionized calcium Every 12 hours: adjust CaCl2 drip.
UF/plasma urea nitrogen Every 12 hours: assess filter efficacy and allow pre-emptive
change in filter if ratio <0.6.
Fluid balance Set goals q 24 hours and monitor and adjust fluid balance by
varying amount of replacement solution hourly to achieve
target balance desired.
arterial pressure. Once a desired value for the hemo-
dynamic parameter is determined, fluid balance can be
linked to that value. For example, if it is desirable to
keep a patient’s PAWP between 14 and 16, a sliding scale
for hourly fluid management can be formulated so that
for PAWP values of 12 to 14, net fluid balance is main-
tained at zero; for values greater than 14, fluid is removed;
for values less than 12, fluid is replaced. In essence, this
method maximally utilizes the ability of CRRT to control
fluid balance. A key issue here is that by incorporating
the desired hemodynamic level, CRRT techniques have
tremendous flexibility and are not simply devices for fluid
removal. They allow overall control of fluid management
as fluid regulatory devices. This external control is a key
advantage over intermittent hemodialysis. We have found
that targeted intervention is easier to achieve, quantitate,
and monitor, and it generally facilitates understanding
among care providers. For example, it is usually easier
to agree on a target hemodynamic parameter such as
PAWP than it is to decide on a patient’s overall volume
status. It is important to emphasize that the continuous
nature of CRRT allows individualization of the fluid bal-
ance prescription. During CRRT there are periods when
fluid balance is required rather than fluid removal, and
it can be necessary to switch the approach from a fluid
removal only to a fluid regulation strategy depending on
the need. The fluid management prescription is therefore
somewhat dynamic and subject to frequent modifications
depending on the clinical condition. It has been our ex-
perience that frequent consultations between intensivists
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and nephrologists on establishing target parameters are
extremely useful in this regard.
Matching the goals of therapy to the therapeutic potential
of CRRT
For any individual patient, immediate and ongoing
goals need to be precisely defined. These depend on a
thorough understanding of the patient’s condition and
the CRRT technique. Definition of fluid goals is a key fac-
tor for the optimal management of critically ill patients.
In practice, this is achieved by an overall assessment of
the patient’s volume status. Often this task is difficult,
as it depends on knowledge of the hydration state (total
body water), the capacity of the circulatory system (resis-
tance and compartmental distribution), and the content
of osmotically active solutes. In critically ill patients, it is
difficult to assess the hydration state, particularly if large
volumes of fluid have been used for resuscitation in short
periods. Records of weights are often erroneous given
the difficulty in weighing patients with multiple tubes on
ventilators, and estimates of fluid losses can be wrong in
patients with large insensible losses (for example, patients
with burns and open wounds). Assessment of circulatory
capacitance is helped by measurement of central filling
pressures, cardiac output, and systemic vascular resis-
tance; however these are prone to measurement error.
While it is possible to assess the solute content by se-
quential measurement of blood chemistries, dilution of
solutes by large volumes of fluid and compartment re-
distribution can significantly affect solute concentrations.
As was apparent in today’s patient, it is fairly common
to find that a patient with marked edema and several
liters of fluid excess has a limited intravascular volume.
In this situation, although fluid removal is required, it
initially might be necessary to maintain an adequate in-
travascular volume by altering the composition of flu-
ids infused (colloids and blood products) and influenc-
ing the systemic resistance. If CRRT is used to remove
fluid without recognition of these factors, the rate of fluid
removal can greatly exceed the capacity of the patient
to mobilize fluid from the interstitial and intracellular
compartments into the intravascular compartment and
will result in hemodynamic instability, as evidenced by
a decrease in blood pressure and organ perfusion. Simi-
larly, an underestimation of the patient’s volume require-
ments could result in an inadequate rate of fluid removal
with resultant worsened fluid overload. In the patient be-
ing discussed, the immediate goals included correcting
acidemia by providing bicarbonate to correct metabolic
acidosis, preventing further fluid overload, and improv-
ing hemodynamic stability. Ongoing goals included fluid
removal, weaning of vasopressors, maintenance of acid-
base and electrolyte balance, and support of organ
function.
Whether to provide dialytic support, and if so, when,
are two of the fundamental questions facing nephrolo-
gists and intensivists in patients with acute renal failure.
Although these decisions are integral to the management
of any critically ill patient with renal failure in the inten-
sive care unit, limited data inform the decision to dialyze.
The decision is often based on an estimation of the likeli-
hood for, and timing of, renal functional recovery. Factors
that influence the likelihood of renal functional recovery
include knowledge of the nature and timing of renal in-
sult, the severity of the underlying illness and associated
co-morbidities, and the presence of other factors known
to adversely influence renal function, such as prolonged
hypotension. Two factors tend to dissuade nephrologists
from initiating dialysis in the intensive care unit. First,
there are well known risks of the dialysis procedure, in-
cluding hypotension, arrhythmia, and complications of
vascular access placement [40]. Second, there is a strong
concern that some element of the dialysis procedure will
slow the recovery of renal function and increase the risk
of end-stage renal failure [41, 42]. Long-standing data
have showed renal lesions consistent with fresh ischemia
in experimental animals and humans dialyzed without
systemic hypotension, long after their initial renal injury
[43, 44]. Thus, in current practice, the decision to dialyze is
most often based on clinical features of volume overload
and biochemical features of solute imbalance (azotemia,
hyperkalemia) [45–47].
When acute renal failure complicates the course of a
critically ill patient in the intensive care unit, it is usually
associated with multiple organ failure, which can influ-
ence the course of the patient in two ways. There can be a
rapid decline of renal function that does not permit much
of an adaptive response as occurs in ESRD; this charac-
terized the course of today’s patient. Second, therapeutic
interventions designed to support other organ function,
for example, volume resuscitation, sometimes exceed the
renal excretory capacity and contribute to a worsening of
the underlying state. In these circumstances, it is apparent
that the goal for any therapeutic intervention is to pro-
vide support for various organs and compensate for the
adverse effects of other therapeutic interventions, thus
providing an opportunity for the patient to recover from
the underlying illness. Renal functional recovery is thus
largely influenced by recovery of other organ function.
Dialysis in this setting has the primary goal of providing
adequate renal support for other organ function. This is
in contrast to the patient with ESRD, in whom the goal
for dialysis is to ameliorate the effects of uremia, and
the determinant for long-term outcome is primarily the
delivery of dialysis.
The CRRT prescription ideally is targeted to match the
therapeutic potential of the technique to specific goals for
the patient. In this patient, the elements of the prescrip-
tion and the circuit are shown in Table 4 and Figure 1,
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respectively. CVVHDF was selected to provide diffusive
and convective clearance of 37 mL/min (approximately
30 mL/kg/hr). Circuit patency was maintained with re-
gional citrate anticoagulation and pre-dilution fluid to
maintain a filtration fraction of 25%. Because the pa-
tient was acidemic, additional bicarbonate (40 mEq/L)
was added as sodium bicarbonate to the dialysate to re-
place the 40 mEq/L of sodium chloride, thereby keeping
the sodium concentration at 117 mEq/L. Fluid balance
was targeted to a central venous pressure of 13 to 15
by varying the amount of replacement fluid given every
hour; the dialysate and fluid compositions were adjusted
to accommodate changes in the patient’s acid-base and
electrolyte status. Table 5 shows the patient’s course for
the first 96 hours after starting CRRT. Eight days after
initiation of therapy, her therapy was changed to inter-
mittent dialysis for continued renal support for oliguric
renal failure. Following three dialysis sessions on consec-
utive days, she became hypotensive again. Continuous
renal replacement therapy was restarted and continued
for 48 hours. On the 16th day after admission, therapy
was held. The patient was given an overall short- and
long-term prognosis, and her parents decided to institute
comfort care measures only. She died shortly thereafter.
This patient’s course illustrates three important con-
cepts. Early intervention with CRRT for support of or-
gan function requires a change in the traditional thought
process of waiting for specific metabolic or biochemical
abnormalities prior to initiation of dialysis. The broad
goals for treating acute renal failure with dialysis are to
(1) maintain fluid and electrolyte, acid-base, and solute
homeostasis, (2) prevent further insults to the kidney, (3)
promote healing and renal recovery, and (4) permit other
support measures (for example, nutrition) to proceed
without limitation. As I said earlier, CRRT techniques
differ in their operational characteristics and their ability
to provide renal support, and these differences should be
considered in the dialysis decision. For instance, CRRT
techniques can be successfully utilized for fluid regula-
tion [18], selective replacement of specific electrolytes,
for example, bicarbonate, without the addition of sodium
or fluid [48], or to add substances to the blood [49]. Sim-
ilarly, the use of combined techniques such as combined
plasma filtration and adsorption for sepsis and cell-based
and hemoperfusion devices for hepatic support devices
is emerging [50–55]. As a consequence, the traditional
indications for renal replacement might need to be re-
defined. For instance, excessive volume resuscitation, a
common strategy used for multi-organ failure, might be
an indication for dialysis even in the absence of significant
elevations in BUN. In this respect it might be more ap-
propriate to consider dialytic intervention in the intensive
care unit patient as a form of renal support rather than
renal replacement. This terminology serves to distinguish
between the strategy for replacing individual organ func-
tion and one to provide support for all organs. It is thus
possible to widen the indications for renal intervention
and provide a customized approach for the management
of each patient. It is also apparent that this approach will
increasingly become the norm as we move into the era of
using dialysis for non-renal problems [12, 49, 56, 57].
A second lesson is that CRRT techniques offer im-
mense flexibility for supporting the changing needs of
critically ill patients. In today’s patient, modifications in
the dialysate and substitutions in fluid composition were
made to optimize her ventilatory management with in-
verse ratio ventilation and permissive hypercapnia. The
traditional way to treat acidosis in this setting is to give
sodium bicarbonate, which contributes to a high sodium
load and consequent sodium and fluid retention. In this
patient, CRRT allowed independent manipulation of
the sodium and bicarbonate composition, keeping the
sodium levels constant and not causing fluid overload.
Correction of her acidemia probably contributed to im-
proved hemodynamic stability, and it likely provided sup-
port for overall organ function. This feature of CRRT
sharply contrasts with intermittent techniques, in which
time and therapy limitations (for example, choice of
dialysate baths) limit the scope of therapeutic maneu-
vers. The varying fluid balance requirements could be
achieved while maintaining hemodynamic stability, thus
utilizing the patient’s underlying state to dictate the ex-
tent of fluid regulation. Control of uremia and mainte-
nance of acid-base and electrolyte balance were similarly
facilitated by the continuous nature of the therapy.
Finally, the decision to intervene with CRRT demon-
strates the multidisciplinary nature of this therapy. Often
it is difficult to ascertain whether provision of dialysis will
substantially change the patient’s outcome [58–60]. The
many physicians involved may differ in their assessment
of the likelihood of success, and often the patient’s fam-
ily requests ongoing support. One approach is to offer a
“trial of therapy” for a specific, pre-defined time period.
Establishing a trial of therapy requires a definition of the
goals, identification of the measurable end points, and a
delineation of specific criteria for evidence of improve-
ment. Agreement should be obtained from all involved
parties (physicians, patients and their family, nurses) for
the time point at which criteria will be evaluated and the
magnitude of change in the measurable criteria accepted
as evidence for improvement [61]. Depending on the pa-
tient’s course, the trial of therapy can be extended for
an additional time interval or a decision made to with-
draw care. This approach has several advantages: it allows
time to evaluate improvement and to provide evidence of
benefit, gives the family time to adjust, resolves conflict,
limits resource utilization, and standardizes the approach
for the caregiver. Ongoing communication is a necessary
step for this approach to be successful. In the patient be-
ing discussed, a trial of therapy was offered for 4 days
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Table 5. Patient course on CRRT
Time Vitals Pertinent labs (Standard units) Comments
At start pH 7.18, PO2 67, PCO2 87, bicarbonate 24 Received 150 mEq bicarbonate IV, on norepinephrine
12 hours Stable hemodynamics
(BP 90/50 mm Hg at
initiation)
pH still low at 7.15, bicarbonate increased to 28 Replacement fluid composition changed from NS to
sodium bicarbonate (150 mEq/L) added to sterile
water. Norepinephrine stopped, fluid removal at −50
mL/hr started
24 hours pH 7.35, pO2 73, pCO2 80, bicarb 44, Na 133, K
3.8, Cl 77, bicarb 40, glu 148, BUN 35, creat 1.3
Weaned off vasopressin, Neosynephrine 80 lg/kg, fluid
balance even for last 24 hours
36 hours BP 100/50 pH 7.34, pO2 101, pCO2 71, bicarb 38 Off Neosynephrine. Fluid balance −500 mL. Targeted
to CVP 13–15. Replacement fluid bicarbonate
reduced to 75 mEq/L. FiO2 reduced to 90%.
48 hours pH 7.34, pO2 79, pCO2 65, bicarbonate 34, PO4
2.9, AST/ALT levels reduced from high of
2405/771
Stable on therapy, replacement started for PO4 of 2.9.
Fluid balance −1200 mL.
96 hours BP 130/60 off pressors FiO2 80%, pH 7.36, pO2 65, pCO2 52, Na 138, K
3.7, Cl 100, bicarb 29, glucose 137, Ca 10.7, PO4
1.9, ionized Ca 1.19 mmol/L, BUN 32, creat 0.7,
T Bil 5.7, WBC 19.1, hemoglobin 10.4, platelets
66; 15 bands, cultures yeast in sputum
Urine output 15 mL/hr, fluid balance targeted to CVP
12–13 cm water, negative balance 2.4 L, replacement
fluid bicarbonate reduced to 50 mEq/L. Routine
filter change. Chest x-ray improved.
with the goals of improved acid-base balance, hemody-
namic stability, and respiratory status assessed by changes
in arterial pH, mean arterial pressure and vasopressor re-
quirements, and oxygen requirements. CRRT techniques
require ongoing and periodic assessments if they are to
be used optimally. It is thus imperative that a team ap-
proach be used for managing patients on CRRT, because
the therapy prescription and delivery are influenced sig-
nificantly by a clear delineation of the operational char-
acteristics. Lack of communication often contributes to
adverse results with these techniques. In this case, the
intensivist and nephrologists met with the patient’s care-
giver and explained the gravity of the patient’s condition
and the elements of the trial of therapy prior to initiation
of CRRT. Following initiation of therapy, daily evalua-
tions and discussions by the intensivists, nephrologists,
and the critical care and nephrology nursing teams were
continued to assess the therapeutic response and modify
the therapy. In essence this is a necessary component of
the care for these patients. Often the simple facts of on-
going communication to set goals, defining the scope of
the therapy, and assessing for response are omitted in the
care of the critically ill. When intermittent dialysis tech-
niques are used, the exposure of the patient and hence
the involvement of the nephrology team at the bedside
are limited to the duration of the therapy.
Continuous renal replacement techniques are now
widely utilized across the world. However, several ques-
tions remain unanswered. Does CRRT have any outcome
benefit [62–64]? Is it cost-effective [65, 66]? What dose
should be utilized [10, 67, 68, 69]? When should therapy
be started [70–72]? When should CRRT not be used [17,
73]? These questions require ongoing research and clin-
ical trials to be effectively answered. While evidence is
being assimilated, consensus statements from the Acute
Dialysis Quality Initiative provide some guidance [73].
As experience with CRRT grows, innovations in technol-
ogy will likely keep pace. Over the last decade, most of
the major manufacturers of dialysis equipment have de-
veloped new pumps for these techniques. Most of these
devices (Gambro/Hospal Prisma; Baxter Accura) offer
automated fluid balancing and sophisticated controls sim-
ilar to those in standard dialysis machines [74]. Mem-
brane technology is also evolving, and adsorbent, highly
permeable membranes are on the horizon [75, 76]. Recent
work in the area of blood flow monitoring suggests that fu-
ture CRRT machines will include ultrasound blood flow
measurement. Such flow measurements can be computer-
linked to the blood pump to ensure correct blood flow,
and a screen display could represent this flow pictorially
[77]. Furthermore, on-line monitoring of filtrate could be
used to indicate urea clearance as a continuous display to
clinicians during therapy [78].
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts Uni-
versity School of Medicine, Boston, Massachusetts): You
mentioned that there is a “common” strategy of fluid
management versus an “alternative” strategy of fluid
management. It seems to me that the common approach,
which I suspect too many of us use, is simply one group
of people handling those multiple hanging plastic bottles
by the patient’s bedside, and the nephrologist handling
the dialysis machine in isolation. The surgeon or the in-
tensivist pours the fluid in and the nephrologist valiantly
tries to keep up with it or maybe even get a liter or two
ahead. How do you, in the real world, manage the po-
tential conflict between the common approach and your
alternative strategy?
DR. MEHTA: Your question is an excellent one. We’ve
developed the alternative strategy, so I’m somewhat bi-
ased toward that approach. The common strategy is used
frequently because when the nephrology team rounds,
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they find the patient has been fluid overloaded four liters,
when the strategy was to try to get them down to zero bal-
ance. A simple approach is to increase the ultrafiltration
rate. However, changes in ultrafiltration rate can be eas-
ily altered by other care providers, such as the surgical
intern who might not have the requisite knowledge of
the system. In addition, you are affecting the clearance,
because the ultrafiltration rates and the effluent volumes
change.
We have found that by keeping the effluent rate con-
stant and varying the replacement fluid, any specific fluid
balance state required by the intensivist can be achieved
with less interference. This strategy requires that the in-
tensivist and nephrologist define a common fluid balance
goal, for example, “the net negative or positive liters at
the end of a particular time period.” Additionally, you
determine which physiologic parameter is most easily
mapped to that fluid balance state, such as PAWP, mean
arterial pressure, or right-ventricular volume. One can
then write a sliding scale for fluid regulation around that
particular parameter. Consequently, the patient charac-
teristics start driving the therapy rather than the physician
trying to second-guess it at periodic intervals.
DR. HARRINGTON: If you look at the mortality rate for
acute renal failure over the last 25 years, it remains hor-
rendously high—anywhere from 25% to 50%. I’ve begun
to call acute renal failure a malignant disease; patients are
dead within two weeks with our kind of malignant dis-
ease, especially acute renal failure complicated by multi-
organ system failure. Yet trials of different treatments
in ARF have been disappointing, for instance, the atrial
natriuretic peptide study. How can we best study differ-
ent drugs, like erythropoietin or minocycline, or different
modalities, such as CRRT, in ARF patients with widely
disparate clinical characteristics?
DR. MEHTA: I think that this is the crux of the problem
for the nephrology community: We do not have a stan-
dard way of defining acute renal failure. We do not look at
acute renal failure as a continuum of these processes; we
look at it as a serum creatinine elevation from a particular
point, and then it’s called acute renal failure. In essence,
it is a change in renal function over a short period of time.
But how we define it has been based largely on serum cre-
atinine levels, which is not the most effective indicator.
So I believe that our first step is to develop a standardized
definition. And I don’t think this definition will be based
on one particular criterion, but will be in more than one
domain. And those domains will include the susceptibil-
ity to injury (predetermined); a second is the nature and
timing of the injury; third would be the response vari-
able, for example, serum creatinine or other marker; and
finally, what else has happened as a consequence of the
injury. If you look at those four domains you come up
with a scoring system similar to the Ransom’s criteria for
pancreatitis and the Child’s C classification for cirrhosis.
We recently proposed a classification that incorporates
these elements [79]. I think if we are able to determine
where the patient is in the course of the illness, we will
have an opportunity to target interventions specifically at
a time point.
DR. HARRINGTON: Who is going to put together that
study, and where is the funding for that study going to
come from? The MDRD study of chronic renal disease
cost $60 million; trials in acute renal failure would be
much more expensive.
DR. MEHTA: Actually, $30 million will be spent by the
Veterans Administration NIH trial on acute renal failure
looking at dialysis dose. I think a partnership between
industry and the NIH would be an obvious source for
funding for this. But we need more observational studies,
and we need more paradigm changes to get to the right
model for us to use.
DR. FRANCIS B. GABBAI (Professor of Medicine, Divi-
sion of Nephrology, University of California, San Diego):
One of the findings in patients with CRRT is that urine
output frequently falls to zero. This is in contrast with
patients treated with intermittent hemodialysis who fre-
quently maintain a low urine output but one seldom as
low as zero. For a long time, we have associated very low
urine output with a bad prognosis in terms of recovery of
renal function. Would you comment on this difference be-
tween CRRT and intermittent hemodialysis, its potential
cause or causes, and its implication in terms of recovery
of renal function?
DR. MEHTA: I’d like to answer that with two specific
viewpoints. One is that you simply could be selecting the
more severely ill patients to go on CRRT who are more
hemodynamically unstable and therefore have less of an
opportunity to make urine. The second is that CRRT
gradually lowers the solute concentrations, which con-
stitute driving forces for osmotic diuresis.
DR. ROBERT W. STEINER (Clinical Professor of
Medicine, Division of Nephrology, University of Califor-
nia, San Diego): Ravi, you discussed the flux of the small
molecules across the dialyzer membrane. Could you com-
ment on calculating the effect of changes in the dialysate
composition and ultrafiltration rate on potassium bal-
ance, for example, and on how to calculate urea removal
in a patient on continuous modalities vis-a-vis nutritional
management?
DR. MEHTA: Since the concentration of solutes in the
effluent mirrors that in the plasma, the total amount
of solute (electrolytes) removed can be computed.
Consequently, the composition of the dialysate or sub-
stitution fluid can be altered to maintain balance. Ad-
ditionally, the urea nitrogen removed by CRRT can be
computed and the protein catabolic rate calculated. Nu-
tritional management in CRRT is an area that I did not
mention in my talk, but it is clearly an important aspect
of the procedure. If you use glucose-based solutions in
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the dialysate or the substitution fluid, the delivered glu-
cose contributes significantly to a caloric load and can
cause hyperglycemia [80]. We have stopped using glu-
cose in the dialysate or substitution fluid for this rea-
son. It is still quite common for people to use a 1.5%
dextrose peritoneal dialysate fluid for the dialysate or a
5% dextrose solution as a substitution fluid, particularly
when you want to lower the serum sodium. In the last
three years, we have started prescribing sterile water with
added bicarbonate (150 mEq/L) rather than using a 5%
dextrose solution as a substitution fluid.
Another factor to be considered is that there is a sig-
nificant amino acid loss across the high permeable fil-
ter. The high fluid removal capacity in CRRT allows any
amount of fluid required for nutritional supplementation
to be administered easily while maintaining fluid balance.
These features permit a high protein and caloric load to
compensate for the catabolic state in acute renal failure.
However, studies by Bellomo et al [81] have shown that
if you go up to 2.0 g/kg or 2.5 g/kg of protein loading, a
positive nitrogen balance cannot be achieved and there
is no additional nutritional benefit. Thus, even though
CRRT permits unlimited nutritional support, there is no
advantage in “overfeeding” patients. On the other hand,
burn patients are usually given very high nutritional sup-
plementation, and in those patients it’s quite a bit easier
to maintain the steady-state BUN levels lower than would
otherwise be possible.
DR. RODRIGO J. FERNANDEZ (Clinical Assistant Pro-
fessor, University of California, San Diego): The present
case would require an ultrafiltration rate of about
2520 mL/hr by Dr. Ronco’s previous study [67]. But even
in that paper only 80% or 85% of the patients were able to
achieve that 35 mL/kg of ultrafiltration. And in practice,
some patients weigh 90 kg or more. How do you techni-
cally achieve such a high ultrafiltration rate considering
that the Gambro Prisma has a maximal blood flow rate
of 180 mL/min that would allow an ultrafiltration rate of
up to 1000 mL/hr at usual settings?
DR. MEHTA: In our patient, the effluent volume was
2500 mL/hr and the ultrafiltration component of that was
500 mL/hr. So we got the same amount of solute clearance
but the equivalent convective clearance of 1500 mL/hr.
That’s one way to get around it if you are looking
purely at small solute clearance. If you wanted to achieve
35 mL/kg/hr of middle molecule clearance, then certainly
you would have to ratchet up the blood flow rates. And
the current versions of some of the machines do make it
limiting for the blood flow rate. But if you want to achieve
that, you have to be conscious of increasing the blood
flow rate, adding predilution, and making sure that your
fluid management strategy is very consistent; otherwise
you have a challenge there. Currently we are exploring
the feasibility of providing higher effluent volumes in a
prospective study, which should provide some answers.
DR. ROBYN CUNARD (Assistant Professor of
Medicine, Division of Nephrology, Veterans Affairs
San Diego Healthcare System and University of Cali-
fornia, San Diego): There is increasing interest on the
part of intensivists to perform CRRT independent of
nephrologists. Is there any evidence that this is a good
practice?
I also have another question. Is the reason that it is
difficult in randomized controlled studies to show a sur-
vival advantage with CRRT compared with IHD related
to the increased incidence of risks associated with this
treatment modality, such as bleeding and infection?
DR. MEHTA: In some countries in the world and a few
centers in the US, this therapy is done purely by inten-
sivists. In the majority of US centers, nephrologists pre-
scribe and perform CRRT. This largely relates to the fact
that CRRT is a dialysis procedure that is specifically in-
cluded in nephrology training. Credentialing for dialysis
in this country has been related to nephrology training;
most intensivists have not had formal training in dialysis
procedures. I think that your question relates to the is-
sue of closed versus open ICUs. Literature supports the
notion that closed ICUs have better outcomes [82]. This
means that if the intensivists handle everything, they have
better outcomes than if other subspecialists come into the
picture. I think, though, that from our own experience, it
is probably better to consider CRRT a multidisciplinary
procedure in which the physicians who do it are well in-
formed and experienced. I hope that in the United States
at least this will remain a multidisciplinary procedure un-
der the control of nephrologists. A recent article from UK
intensivists showed that only about 8% of the patients
who were in the ICU with intermittent hemodialysis, and
the nephrologists were generally not involved in that care
[83].
Your second question, related to complications, is a
very important one. Here’s the difficulty: when you use
a continuous therapy in a critically ill patient, who is al-
ready prone to a lot of adverse events, how do you know
whether a complication was because of the therapy or
because of the underlying disease process? That’s the
biggest question we have. We know that acute renal fail-
ure itself contributes to adverse outcomes, such as sepsis
and death, and that dialyzed patients have a higher risk.
No one, however, has addressed the question of why this
is the case and whether complications contribute to the
risk. We are exploring these issues.
DR. HARRINGTON: Early in your discussion you men-
tioned adsorption of substances into the membrane itself
as one of the reasons for utilizing CRRT as renal replace-
ment therapy, because time is on your side. Could you
give us an example of that?
DR. MEHTA: There has been an intense interest in try-
ing to use these therapies for treating sepsis, even in the
absence of renal dysfunction. We know that cytokines are
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released in this setting and that they are removable by the
membranes by adsorption. So it’s quite feasible that if you
could apply CRRT, you might be able to lower cytokine
levels. Studies have demonstrated, however, that chang-
ing the filters every 12 hours might be required to reduce
cytokine levels [13, 14]. However, the difficulty is know-
ing when to use CRRT in that situation, knowing what
level you’re going to remove, and being selective about it
[12, 56].
DR. CLAYTON SMILEY (Fellow, Division of Nephrol-
ogy, University of California, San Diego): When anticoag-
ulating the circuit on CRRT, some individuals use citrate
and others use heparin; is there an advantage to one ap-
proach versus the other?
DR. MEHTA: Yes; several published studies, including
our own experience, clearly demonstrate that citrate an-
ticoagulation offers better filter life, better filter perfor-
mance, and less bleeding risk in comparison to heparin
[23]. This has now been shown for both CVVHDF cir-
cuits and CVVH circuits. In fact, a recent article looked
at a randomized controlled trial of heparin versus citrate
in CVVH and showed that citrate anticoagulation pro-
duced less filter clotting [39].
DR. MITA SHAH (Fellow, Division of Nephrology, Uni-
versity of California, San Diego): Replacement fluid is
often administered in high volumes to patients who are
hypoalbuminemic. Most often crystalloid, are these solu-
tions contributing to the volume overload of these CRRT
patients? Can you discuss alternative replacement fluid
strategies?
DR. MEHTA: In our CRRT system, we prescribe crys-
talloids predominantly because of the expense of using
colloids. But there is certainly room for changing some
part of the volume replacement to colloids, as is done in
some patients, particularly those with liver disease who
are getting fresh frozen plasma (FFP) or albumin solu-
tions. But no good data, even in the absence of CRRT,
suggest that using colloids has a marked benefit over us-
ing these crystalloids. What is emerging, though, is small-
volume resuscitation with hypertonic saline, because it
tends to reduce endothelial swelling; these solutions have
not been tried in CRRT.
DR. HARRINGTON: In the last few years, studies in in-
tensive care unit patients have shown that rigorous con-
trol of blood sugar leads to a significant fall in mortality
rates and decreases the likelihood of ARF [84]. My spe-
cific question is, does CRRT help or hurt in controlling
blood sugar in these critically ill patients?
DR. MEHTA: If you use glucose solutions for substitu-
tion fluid or dialysate, you’re contributing to the hyper-
glycemic load of these patients. To my knowledge, no sin-
gle study has looked at hyperglycemia or glucose control
in CRRT as a separate issue for this population. But it is
certainly a very intriguing question and I think it deserves
more attention. A study by Bellomo about a decade ago
showed that patients on CRRT who had high insulin lev-
els had a worse outcome, and suggested that metabolic
control is a major issue in these patients [85].
DR. NICHOLAS ROWDER (Fellow, Division of Nephrol-
ogy, University of California, San Diego): You have dis-
cussed when it is reasonable to start CVVHD, but besides
a patient becoming hemodynamically stable, are there
other factors that would make you stop CVVHD and
switch treatment to intermittent dialysis?
DR. MEHTA: To my knowledge, only one study has ad-
dressed this specifically; I’ll get to that in a moment. Clin-
ically the issue is: Can you have adequate hemodynamic
stability and an improved catabolic state, such that you
can get away from using CRRT? And this is partially a re-
sponse also to Dr. Steiner’s question. You could do a urea
nitrogen appearance rate and calculate a catabolic rate.
That parameter can quite clearly tell you when CRRT
will still be required because, if you are still getting a
protein catabolic rate of 1.5 to 2.0 g/kg, there’s no way
you’re going to be able to maintain the same level of
steady-state solute balance without continuing CRRT. In
addition, fluid management is a key determinant; so even
if patients might otherwise be getting better, if they still
require large amounts of fluids to be removed, that might
be better accomplished with CRRT.
A study from the University of Alabama was shown at
the CRRT conference last year [86]. They have 14 CRRT
machines, so they’re basically doing CRRT on 5 to 10 pa-
tients every day. They had looked at this question and
they measured creatinine clearances. When the creati-
nine clearance was about 15 mL/min, that seemed to be
a cutoff when you could easily stop CRRT. No one else
has looked at it in that way, but I think that’s a reasonable
approach to utilize and further examine.
DR. HARRINGTON: Ravi, perhaps you can end provid-
ing us with the best reference regarding the terminology
and definitions of renal replacement therapy.
DR. MEHTA: I would recommend the ADQI consensus
statement regarding CRRT [73].
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